COVID-19 Antivirals pregnancy registry
In collaboration with all UK Health Departments and the Medicines and Healthcare products Regulatory Agency (MHRA), UKTIS are monitoring the safety of new COVID-19 antivirals when taken in or around pregnancy.
Who can report to the registry?
- Healthcare professionals
- Pregnant women
- Partners of pregnant women
If you live in the UK and (1) you have a patient that has used a COVID-19 antiviral medication when they were pregnant or shortly before pregnancy, or (2) if you used a COVID-19 antiviral medication when you were pregnant, or (3) if you used a COVID-19 antiviral medication around the time your partner conceived, please report the pregnancy to UKTIS today.
To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).
How does the registry work?
- Healthcare professionals and pregnant women/partners of pregnant women in England, Scotland and Wales can report pregnant women or the partners of pregnant women who used COVID-19 antivirals either during pregnancy or around the time of conception to UKTIS. This reporting does not require consent from the patient (England and Wales – Section 251 Exemption – PHE CAP approval number 13091, Scotland – approval pending). Reported pregnancies are subsequently followed-up using standardised procedures.
- Healthcare professionals in Northern Ireland cannot currently report pregnant women to the registry. However, pregnant women and partners of pregnant women who have used COVID-19 antivirals during pregnancy or around the time of conception can self-report their pregnancy to UKTIS.
For more information about how the registry works, see here.
To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).
Information about the safety of COVID-19 antivirals
If you are looking for information about the safety of COVID-19 antivirals, please see our information sources below:
Summary Information for Healthcare Professionals
Molnupiravir (manufacturer information: Lagevrio)
Paxlovid (nirmatrelvir/ritonavir – see COVID-19 antivirals section)
Summary Information for Patients
Molnupiravir (manufacturer information: Lagevrio)
Paxlovid (manufacturer information: Paxlovid)
Information about COVID-19 antiviral clinical trials